EDELMAN JOSEPH 4
4 · Athira Pharma, Inc. · Filed Sep 22, 2020
Insider Transaction Report
Form 4
EDELMAN JOSEPH
Director
Transactions
- Conversion
Series B Preferred Stock
2020-09-22−1,644,785→ 0 total(indirect: See Footnote)→ Common Stock (1,644,785 underlying) - Conversion
Common Stock
2020-09-22+1,644,785→ 2,055,981 total(indirect: See Footnote) - Purchase
Common Stock
2020-09-22$17.00/sh+1,058,824$18,000,008→ 3,114,805 total(indirect: See Footnote)
Footnotes (2)
- [F1]Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- [F2]The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Mr. Edelman disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.